Pediatrix Medical Group, INC Form 4 insider transactions

David Haddock, EVP, GC & Corp Sec of Pediatrix Medical Group, Inc., was granted restricted shares and performance share units.

EVP and General Counsel Mary Ann E. Moore transferred 18,407 shares of Pediatrix Medical Group common stock to a family trust.

Kasandra H. Rossi, EVP, CFO and Treasurer of Pediatrix Medical Group, Inc., reported transactions involving restricted stock grants and tax withholdings.

Pediatrix Medical Group, Inc. Chief Executive Officer Mark S. Ordan reports transactions involving restricted stock, including grants and tax withholdings.

Don Gregory Neeb, EVP Chief Invest & Strategy at Pediatrix Medical Group, Inc., reported transactions involving restricted stock and tax withholdings.

Pediatrix Medical Group, Inc. executive Mary Ann E. Moore reported a transaction involving common stock, including shares withheld for tax payments.

Pediatrix Medical Group Director Shirley A. Weis reported a sale of 36,028 shares of common stock on May 13, 2026, for a weighted average price of $23.75 per share.

Pediatrix Medical Group Director Thomas McEachin reported a transfer of 11,427 shares of common stock to a trust for which he and his spouse are trustees and beneficiaries.

Mary Ann E. Moore, EVP and General Counsel of Pediatrix Medical Group, transferred 40,826 shares to a family trust.

Director Michael A. Rucker was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. common stock.

Director Laura A. Linynsky was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. common stock.

Director Guy P. Sansone was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.

Director Sylvia Jean Young was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.

Director John M. Starcher Jr. was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.

Director Shirley A. Weis was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.

Director Thomas McEachin was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.

Director Kurt Douglas Newman acquired 7,196 shares of Pediatrix Medical Group, Inc. common stock via an annual equity award.

Pediatrix Medical Group CEO Mark S. Ordan reported the sale of 23,000 shares of common stock for a weighted average price of $22.41 per share.

Pediatrix Medical Group Director Michael A. Rucker sold 10,478 shares of common stock for $23.00 per share.

Pediatrix Medical Group Director Laura A Linynsky plans to sell 10,000 shares of common stock for $21.65 per share on November 6, 2025, under a pre-arranged Rule 10b5-1 plan.

Pediatrix Medical Group Director Thomas McEachin transferred a total of 54,646 shares of common stock to a living trust in August 2025.

Pediatrix Medical Group's EVP of Investment and Strategy, Don Gregory Neeb, received significant equity awards including restricted shares and performance share units.

Pediatrix Medical Group Director Kurt Douglas Newman was granted 9,737 restricted shares of common stock as part of an annual equity award.

Mary Ann E. Moore, EVP, General Counsel, Chief Administrative Officer & Secretary of Pediatrix Medical Group, Inc., reported the transfer of 10,371 shares of common stock to a family trust.

Pediatrix Medical Group's EVP, CFO, and Treasurer, Kasandra H. Rossi, was granted 26,502 restricted shares as part of an annual equity award, aligning her incentives with the company's long-term performance.

Pediatrix Medical Group, Inc. (MD) CEO Mark S. Ordan was granted 194,347 restricted shares as part of an annual equity award, aligning executive incentives with shareholder interests.

Pediatrix Medical Group's EVP, General Counsel, Chief Administrative Officer, and Secretary, Mary Ann E. Moore, reported the acquisition of 53,004 restricted shares as an annual equity award and the disposition of 6,729 shares for tax withholding.

Shirley A. Weis, a Director at Pediatrix Medical Group, Inc., has transferred 18,360 shares of common stock to a family trust, maintaining her overall beneficial ownership.

CEO Mark Ordan reports disposition of shares to cover tax obligations upon vesting.

Director Sylvia Jean Young reports acquisition of 11,427 shares of Pediatrix Medical Group, Inc. common stock on May 8, 2025, as part of an annual equity award.